A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.
Mark J. Levis(Sidney Kimmel Cancer Center), Donald Small(Sidney Kimmel Comprehensive Cancer Center), Miloslav Beran(The University of Texas MD Anderson Cancer Center), Steven Coutré(Georgetown University), Robert K. Stuart(Memorial Sloan Kettering Cancer Center), Larry D. Cripe(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Peter de Nully Brown(Copenhagen University Hospital), Marcel P. Devetten(University of Nebraska at Omaha), Maria R. Baer(University of Maryland, Baltimore), Harry P. Erba(Michigan Center for Translational Pathology), Lothar Tremmel, Anjali S. Advani(Cleveland Clinic), Alexander E. Perl(University of Pennsylvania), B. Douglas Smith(Johns Hopkins University)
Cited by 57
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k